Live Breaking News & Updates on Embolic Protection System|Page 2

Stay updated with breaking news from Embolic protection system. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

CGuard Carotid Embolic Protection Device Trial Will be Led by Chris Metzger


CGuard Carotid Embolic Protection Device Trial Will be Led by Chris Metzger
InspireMD s MicroNet embolic protection mesh on stents is designed to prevent emboli during carotid stenting.
February 9, 2021 InspireMD Inc., developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced the appointment of Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee as the principal investigator for its planned U.S. FDA registration trial for CGuard EPS.
This upcoming trial will investigate the safety and efficacy of InspireMD s MicroNet embolic protection system technology for carotid stenting. It is designed to prevent stroke during stent placement and help improve long-term outcomes.  ....

United States , Holston Valley , Chris Metzger , Marvin Slosman , Gary Roubin , Ballard Health Systems , Ballad Health System , Inspiremd Inc , Catheterization Labs At Holston Valley Medical Center , Embolic Prevention System , Eastern Tennessee , Diagnostic Catheterization Labs , Holston Valley Medical Center , Embolic Protection System , ஒன்றுபட்டது மாநிலங்களில் , ஹோல்ஸ்டன் பள்ளத்தாக்கு , கிறிஸ் மெதஜ்கேர் , கேரி ரூபின் , பாலார்ட் ஆரோக்கியம் அமைப்புகள் , பாலாட் ஆரோக்கியம் அமைப்பு , வடிகுழாய் ஆய்வகங்கள் இல் ஹோல்ஸ்டன் பள்ளத்தாக்கு மருத்துவ மையம் , கிழக்கு டென்னசி , கண்டறியும் வடிகுழாய் ஆய்வகங்கள் , ஹோல்ஸ்டன் பள்ளத்தாக்கு மருத்துவ மையம் ,

InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China


Share:
TEL AVIV, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) InspireMD, Inc. (NYSE:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announced a transaction intended to achieve distribution of CGuard EPS in mainland China.
InspireMD s agreement with three China-based investment partners, including Shanghai Micro Medical (SMM) and QIDI Asia Medical, stipulates that the Chinese partners will be responsible for conducting all necessary registration trials for commercial approval, followed by an eight-year exclusive distribution right in China. In addition, QIDI has agreed to make a $900,000 investment in InspireMD s common stock at the closing price on the day immediately prior to entering into the transaction in a private placement. The transactions are expected to close this month. Following announcement of the transaction the Chinese partners plan to initiate the process of securing reg ....

United States , Marvin Slosman , Tony Liu , Company Annual Report On Form , Exchange Commission , Health Research International Market , Inspiremd Inc , Embolic Prevention System , Shanghai Micro Medical , Securities Act , Embolic Protection System , Annual Report , Quarterly Reports , Research International Market , ஒன்றுபட்டது மாநிலங்களில் , டோனி லியூ , நிறுவனம் ஆண்டு அறிக்கை ஆன் வடிவம் , பரிமாற்றம் தரகு , ஆரோக்கியம் ஆராய்ச்சி சர்வதேச சந்தை , ஷாங்காய் மைக்ரோ மருத்துவ , பத்திரங்கள் நாடகம் , ஆண்டு அறிக்கை , காலாண்டு அறிக்கைகள் , ஆராய்ச்சி சர்வதேச சந்தை ,